Food allergy therapeutics Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief
What This Brief Covers
This Meticulous Next™ brief examines food allergy therapeutics, meaning prescription treatments that reduce reactions to accidental exposure in people with IgE-mediated food allergy. These include anti-IgE biologics, oral and other allergen immunotherapies and new antibody therapies. It tests how fast care moves from allergen avoidance and oral immunotherapy toward biologic treatment, and which participants capture value among therapy developers, allergists, health systems and investors.
One approved biologic now leads. The FDA approved Xolair (omalizumab) on 16 February 2024 for adults and children aged one year and older with IgE-mediated food allergy, as its fourth indication. In the NIH-sponsored OUtMATCH phase III trial, 68% of patients on Xolair tolerated a 600 mg peanut dose without moderate to severe symptoms against 5% on placebo, and the results were 66% against 11% for milk, 67% against 0% for egg and 42% against 3% for cashew. The conclusion is that one medicine protects against several foods at once, which a food by food approach to immunotherapy cannot do.
Oral immunotherapy has stepped back. Stallergenes Greer, which acquired Palforzia from Nestlé in September 2023, announced in January 2026 that production would stop and ended the product on 31 July 2026, leaving no FDA-approved peanut oral immunotherapy. The company said the decision was not related to safety, quality or efficacy, and pointed to the complex protocol and the REMS programme. The conclusion is that treatment burden decided the outcome of the first approved therapy, and new products must be easier to prescribe and take.
Competition is forming around the same target. A biosimilar of omalizumab, Omlyclo, is expected to launch in the fall of 2026, and GSK holds ozureprubart, an anti-IgE antibody dosed every 12 weeks and in early trials, after its purchase of RAPT Therapeutics in January 2026. The second stage of OUtMATCH, reported in July 2026, found that omalizumab outperformed multiallergen oral immunotherapy in people with several food allergies. The conclusion is that anti-IgE therapy is the main platform, and the next gains come from price, dosing interval and duration of benefit.
The brief treats food allergy therapeutics as an accelerating signal with an eight year horizon to 2034. It identifies which therapies, regions and operators scale first and what each means for developers, allergists, health systems and investors. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.
| Parameter | Details |
|---|---|
| Forward horizon | 2026–2034 (8 years) |
| Emerging force | Food allergy therapeutics: omalizumab approval and early-introduction guidance changing care |
| Technology readiness | One biologic approved for multiple food allergies; oral immunotherapy withdrawn; biosimilar and longer acting anti-IgE therapies in preparation |
| Indicative market size & forecast | The food allergy therapeutics market, covering anti-IgE biologics, oral and other allergen immunotherapies and new antibody therapies prescribed for IgE-mediated food allergy, and excluding emergency epinephrine products, diagnostics and food products, is valued at USD 0.4–0.7 billion in 2026 and is projected to reach USD 1.72–3.01 billion by 2034, at a CAGR of 20% |
| Mainstream inflection | ~2030, when biosimilars and longer acting anti-IgE therapies make biologic treatment routine |
| Signal strength | FDA approval for multiple food allergies, trial results in four foods and a biosimilar launch expected in fall 2026 |
| Primary beneficiaries | Developers with approved biologic therapy; biosimilar producers; developers of longer acting therapy |
| Brief length / format | 104 pages · PDF + executive summary deck · instant delivery |
Understanding the Technology
Food allergy therapeutics are prescription treatments that raise the amount of a food a patient can tolerate before a reaction, or reduce the severity of reactions after accidental exposure.
Anti-IgE biologics such as omalizumab block IgE, the antibody behind the reaction, and protect against several foods at once. Oral immunotherapy gives small and rising doses of a single food.
Performance depends on protection against accidental exposure, treatment burden and adherence, and how long benefit lasts after stopping.
Uses are peanut and multi-food allergy in children and adults, with early introduction guidance aimed at preventing allergy in infants.
The limits are the cost of biologics, the need for continued allergen avoidance, the withdrawal of oral immunotherapy and safety warnings for anaphylaxis. The period turns on biosimilars and on longer acting therapies.
Market Outlook
The food allergy therapeutics market, covering anti-IgE biologics, oral and other allergen immunotherapies and new antibody therapies prescribed for IgE-mediated food allergy, and excluding emergency epinephrine products, diagnostics and food products, is valued at USD 0.4–0.7 billion in 2026 and is projected to reach USD 1.72–3.01 billion by 2034, at a CAGR of 20%.
The 2026 base rests on sales of omalizumab for food allergy and on remaining oral immunotherapy use. Growth then follows biosimilar launches, new anti-IgE therapies and wider use in people with several food allergies.
The forecast is sensitive to price after biosimilar entry, payer coverage and the pace of new approvals. Regionally, North America leads on approval and use, Europe on guidelines and review, and Asia-Pacific on future access.
Scenarios
The base case assumes biosimilar launches from 2026 and approval of a longer acting anti-IgE therapy by 2030. An accelerated case assumes quick biosimilar uptake and early approval of new antibodies, bringing the inflection to 2028 and lifting the 2034 value to the top of the range. A delayed case assumes slow payer coverage and safety setbacks, holding growth at the bottom of the range.
Factors Behind Growth
Growth drivers
- Approved biologic therapy.
- Evidence in multiple food allergies.
- Early introduction guidance.
- Pipeline of anti-IgE therapies.
Enablers
- Public research funding.
- Allergist networks.
- Biosimilar launches.
- Patient advocacy organisations.
Restraints and barriers
- Cost of biologic therapy.
- Need for continued allergen avoidance.
- Withdrawal of oral immunotherapy.
- Safety warnings for anaphylaxis.
The Forces at Play
The direction of food allergy therapeutics is set by the approval of omalizumab for food allergy, the withdrawal of oral immunotherapy, biosimilar competition, early introduction guidance and clinical trial evidence in multiple food allergies.
Adoption Outlook
How the shift is likely to unfold across three time horizons.
Care moves from oral immunotherapy to biologics and the first biosimilars launch.
New and longer acting anti-IgE therapies are approved and dosing intervals lengthen.
Biologics are standard care for severe and multiple food allergy.
Latest Strategic Developments
| Date | Development | Type | Significance |
|---|---|---|---|
| Feb 2024 | The FDA approves Xolair (omalizumab) to reduce allergic reactions to accidental exposure in adults and children aged one year and older with IgE-mediated food allergy | Regulatory approval | Creates the first approved biologic therapy for multiple food allergies |
| Mar 2025 | Palforzia is expanded to include toddlers | Label expansion | Extends oral immunotherapy to the youngest children shortly before its withdrawal |
| Jan 2026 | Stallergenes Greer announces that production of Palforzia will stop after a strategic review | Withdrawal | Signals the retreat of oral immunotherapy |
| Jan 2026 | GSK buys RAPT Therapeutics and its anti-IgE antibody ozureprubart, dosed every 12 weeks and in early trials | Acquisition | Adds a longer acting anti-IgE candidate to a large developer |
| Jul 2026 | The second stage of the OUtMATCH trial finds omalizumab outperformed multiallergen oral immunotherapy in people with several food allergies | Trial result | Supports biologic therapy over immunotherapy in multiple food allergy |
| Jul 2026 | Stallergenes Greer ends Palforzia on 31 July 2026, leaving no FDA-approved peanut oral immunotherapy | Withdrawal | Leaves omalizumab as the lead approved therapy |
Key Players & Competitive Landscape
The key participants in food allergy therapeutics include Novartis AG, Roche Holding AG, Stallergenes Greer plc, Nestlé S.A., GSK plc, Celltrion, Inc., DBV Technologies S.A., ALK-Abelló A/S, Allergy Therapeutics plc, Aravax Pty Ltd, Alladapt Immunotherapeutics, Inc., Jasper Therapeutics, Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Amneal Pharmaceuticals, Inc., Kashiv Biosciences, LLC, Prota Therapeutics Ltd, Intrommune Therapeutics, Inc., Ukko Inc., National Institute of Allergy and Infectious Diseases, Johns Hopkins University, Stanford University, Massachusetts General Hospital, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Health Canada, Pharmaceuticals and Medical Devices Agency of Japan, National Medical Products Administration of China, American Academy of Allergy, Asthma & Immunology, European Academy of Allergy and Clinical Immunology, American College of Allergy, Asthma and Immunology, World Allergy Organization, Food Allergy Research & Education, Asthma and Allergy Foundation of America, Food Allergy Canada and Allergy UK.
The brief profiles representative participants in each archetype and assesses which are positioned to lead as food allergy care changes.
Novartis and Roche lead on the approved biologic, Celltrion leads among biosimilar developers, and GSK holds a longer acting candidate. Competitive intensity is low in 2026 and rises as biosimilars launch.
| Archetype | Representative players | Position | Outlook |
|---|---|---|---|
| Biologic and immunotherapy developers | Novartis, Roche, Stallergenes Greer, GSK, DBV Technologies, ALK-Abelló, Allergy Therapeutics, Aravax, Alladapt Immunotherapeutics, Jasper Therapeutics, Sanofi, Regeneron | Anti-IgE biologics, immunotherapy and new antibodies | Develop and sell prescription therapies |
| Biosimilar and early stage developers | Celltrion, Teva, Amneal, Kashiv Biosciences, Prota Therapeutics, Intrommune Therapeutics, Ukko | Omalizumab biosimilars and early stage allergy therapies | Bring lower priced and new therapies to market |
| Food and nutrition companies | Nestlé | Allergen foods and nutrition | Support early introduction and nutrition |
| Universities and research bodies | National Institute of Allergy and Infectious Diseases, Johns Hopkins University, Stanford University, Massachusetts General Hospital | Clinical trials and mechanisms | Generate clinical evidence |
| Government agencies and regulators | U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Health Canada, Pharmaceuticals and Medical Devices Agency of Japan, National Medical Products Administration of China | Approvals and safety review | Approve therapies and set safety programmes |
| Associations and advocacy groups | American Academy of Allergy, Asthma & Immunology, European Academy of Allergy and Clinical Immunology, American College of Allergy, Asthma and Immunology, World Allergy Organization, Food Allergy Research & Education, Asthma and Allergy Foundation of America, Food Allergy Canada, Allergy UK | Guidelines and patient support | Set guidance and represent patients |
Where value migrates.
In 2026 value sits with developers of the approved biologic, because it is the only approved medicine for several food allergies and the only option left after the withdrawal of oral immunotherapy. By 2030 it moves toward biosimilar producers and developers of longer acting therapy, because price and dosing interval decide how many patients are treated. By 2034 it settles in multi-allergen standard of care that combines biologic therapy, monitoring and early introduction guidance. Margins hold for developers with differentiated dosing and fall for those that sell an undifferentiated copy.
Who Will Win — and Why
The archetypes best positioned to capture value as the shift matures.
Firms with an approved anti-IgE medicine and evidence in several foods.
Firms that bring lower priced omalizumab to payers and allergists.
Firms with antibodies dosed every 12 weeks or less often.
Regulatory Landscape
| Jurisdiction | Milestone | Indicative timing | Effect on adoption |
|---|---|---|---|
| FDA approval of omalizumab for food allergy | Approval on 16 February 2024 for ages one year and older | In force | Allows prescription of a biologic for several foods |
| Withdrawal of Palforzia | Production stopped and product ended on 31 July 2026 | In force | Removes peanut oral immunotherapy from the US market |
| Biosimilar approvals | Omalizumab biosimilar Omlyclo expected to launch in fall 2026 | Emerging | Brings price competition to the lead biologic |
| Clinical guidelines for food allergy | Practice guidance on treatment and early introduction | Emerging | Decides how fast new therapies enter routine care |
| Reimbursement of biologic therapy | Payer coverage rules for anti-IgE therapy | Emerging | Decide patient access and uptake |
Investment Signals
The signals converge on a shift from immunotherapy to biologics. An approved anti-IgE medicine, trial results in four foods, the withdrawal of oral immunotherapy and a biosimilar launch expected in fall 2026 support growth, while cost, the need for continued allergen avoidance and safety warnings limit the pace.
Structural limits show where progress could slow: the cost of biologics, the need for continued allergen avoidance, the withdrawal of oral immunotherapy, and safety warnings for anaphylaxis. The brief therefore tracks four indicators: biosimilar launches, new approvals, payer coverage, and trial readouts.
Peanut and multi-food allergy in children first, then adults, then prevention in infants are the expected order of adoption.
Questions This Brief Answers
Strategic Implications
- Therapy developers: build evidence in several foods and aim for longer dosing intervals and easier use than oral immunotherapy.
- Allergists and health systems: plan pathways for biologic therapy, monitoring and the transfer of patients from oral immunotherapy.
- Investors and funders: back developers with differentiated dosing, and treat biosimilar price competition as the main risk.
- Policy makers and regulators: review biosimilars on a clear timetable and keep guidelines and coverage rules up to date.
- Food and nutrition companies: support early introduction guidance with clear labelling and products.
"Oral immunotherapy showed that treatment was possible. Biologics will decide how many patients can actually take it."
Table of Contents
Access & Licensing
A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.
every brief